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OBJECTIVE—To evaluate whether healthy or diabetic adult
mice can tolerate an extreme loss of pancreatic a-cells and how
this sudden massive depletion affects b-cell function and blood
glucose homeostasis.
RESEARCH DESIGN AND METHODS—We generated a new
transgenic model allowing near-total a-cell removal speciﬁcally in
adult mice. Massive a-cell ablation was triggered in normally
grown and healthy adult animals upon diphtheria toxin (DT) ad-
ministration. The metabolic status of these mice was assessed in
1) physiologic conditions, 2) a situation requiring glucagon action,
and 3) after b-cell loss.
RESULTS—Adult transgenic mice enduring extreme (98%) a-cell
removal remained healthy and did not display major defects in
insulin counter-regulatory response. We observed that 2% of the
normal a-cell mass produced enough glucagon to ensure near-
normal glucagonemia. b-Cell function and blood glucose homeosta-
sis remained unaltered after a-cell loss, indicating that direct local
intraislet signaling between a- and b-cells is dispensable. Escaping
a-cells increased their glucagon content during subsequent
months, but there was no signiﬁcant a-cell regeneration. Near-total
a-cell ablation did not prevent hyperglycemia in mice having also
undergone massive b-cell loss, indicating that a minimal amount of
a-cells can still guarantee normal glucagon signaling in diabetic
conditions.
CONCLUSIONS—An extremely low amount of a-cells is sufﬁ-
cient to prevent a major counter-regulatory deregulation, both un-
der physiologic and diabetic conditions. We previously reported
that a-cells reprogram to insulin production after extreme b-cell
loss and now conjecture that the low a-cell requirement could be
exploited in future diabetic therapies aimed at regenerating b-cells
by reprogramming adult a-cells. Diabetes 60:2872–2882, 2011
In rodents, glucagon-producing a-cells are the secondmost abundant endocrine cell type in pancreaticislets of Langerhans, after the insulin-producing b-cells.In human islets, a-cells are nearly as abundant as
b-cells (1,2). They secrete glucagon in response to reduced
blood glucose to promote gluconeogenesis and glycogen-
olysis in the liver (3). Proper control of blood glucose level
thus relies on insulin action and the counter-regulation
mediated by glucagon signaling. Besides this, insulin and
glucagon reciprocally regulate a- and b-cell function through
local, intraislet paracrine signaling (4).
Excess of plasma glucagon (hyperglucagonemia) is fre-
quently reported in diabetic patients, a deregulation that
exacerbates hyperglycemia and triggers ketoacidosis, a ma-
jor complication of diabetes (5). A recent study showed that
streptozotocin (STZ)-induced diabetes is prevented in glu-
cagon receptor–knockout (GcgR2/2) mice, suggesting that
in diabetes, hyperglycemia is largely due to glucagon action
(6). Therefore, reducing the a-cell mass to limit glucagon
production may represent an interesting approach to pre-
vent glucagon excess in diabetes. Nevertheless, it is un-
known how a severe decrease in pancreatic a-cell mass
would be tolerated in physiologic or in diabetic conditions.
Indeed, whereas a strong deﬁcit in b-cell mass triggers di-
abetes, less is known regarding the requirement of main-
taining intact the adult a-cell population.
Complete disruption of glucagon signaling in GcgR2/2
mice is associated with defects in endocrine cell differ-
entiation and increased embryonic lethality (7–9). In ad-
dition, mice that are unable to process proglucagon in its
mature and active form due to prohormone convertase
2 (PC2) inactivation also display altered islet cell differ-
entiation (10,11). GcgR2/2 and PC22/2 adult mutant mice
both exhibit an expanded a-cell mass, which is associated
with lower blood glucose levels.
Mice constitutively lacking aristaless-related homeobox
(ARX) in the pancreas from early development display an
a-cell deﬁcit associated with abnormally increased non–a-cell
numbers and hypoglycemia (12). In this situation, the altered
metabolic status of adult individuals may reﬂect adaptation
phenomena subsequent to developmental defects. Collec-
tively, these studies that focused on the effect of glucagon
deﬁciency did not directly address whether functional a-cells
are essential per se for proper b-cell function and blood
glucose homeostasis in physiologic conditions in adulthood.
In the current study, we have analyzed a model of induc-
ible, selective a-cell loss that we previously used in studies
involving b-cell regeneration (13). Here, we examine the short-
and long-term inﬂuence on blood glucose homeostasis of an
acute, rapid, near-total a-cell ablation induced in healthy
normal adult mice. We show that a very limited number of
adult a-cells, some 2% of the normal a-cell mass, is sufﬁcient
to preserve a normal counter-response to insulin in basal con-
ditions, without affecting b-cell function or longevity. Fur-
thermore, we report that extreme a-cell removal, contrary
to what happens in GcgR2/2 mice (6), does not prevent hy-
perglycemia after b-cell loss, indicating that the few remain-
ing a-cells still mediate normal glucagon signaling in diabetes.
RESULTS
Ablation of a-cells.We previously generated the Glucagon-
DTR mouse line in which the administration of diphtheria
toxin (DT) induces selective and massive ablation of adult
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a-cells (13). This is achieved through the transgenic ex-
pression of human DT receptor (DTR) on the a-cell surface,
driven by a 1.6-kb proximal fragment of the rat glucagon
promoter (Fig. 1A).
DT-untreated adult Glucagon-DTR mice were healthy
and showed normal blood glucose homeostasis, like non-
transgenic controls. For this reason, they were well suited
for studying the effect of extreme a-cell mass deﬁcit in
metabolically unbiased adult animals.
Histologically, Glucagon-DTRmice exhibited normal islet
architecture, with peripheral a-cells and no detectable islet
cell death (Fig. 1A). By contrast, numerous apoptotic islet
cells were seen in Glucagon-DTR mice 2 days after one DT
injection (500 ng). One week after 3 DT injections (1,500 ng;
see RESEARCH DESIGN AND METHODS), the vast majority of islets
were totally devoid of a-cells (Fig. 1A, bottom). We mea-
sured a-cell ablation efﬁciency by morphometry and pan-
creatic hormone dosage and found the number of a-cells
and pancreatic glucagon content were decreased by 97.9%
and 99.14%, respectively (Fig. 1B and C and Table 1). In
agreement with results obtained using the Glucagon-Cre
and Glucagon-rtTA mouse lines, which bear the same rat
glucagon promoter fragment (14), we detected transgene ex-
pression solely in pancreatic a-cells. Therefore, b-, d-, PP-, as
well as intestinal L cells, were normally present after DT
treatment in Glucagon-DTRmice (Supplementary Figs. 1 and
2A). The L cells were not eliminated with DT treatment be-
cause “intestinal-speciﬁc” cis-regulatory elements of the glu-
cagon promoter (located ;2.0-kb upstream of the start site)
are absent in the transgene (15). Altogether, these results
showed that a-cell ablation is speciﬁc and efﬁcient.
In all experiments described below, only 2-month-old
male mice were used. When indicated, these animals re-
ceived 1.5 mg of DT (i.e., 3 i.p. injections).
Blood glucose regulation is unaffected after extreme
a-cell ablation. A follow-up of DT-treated Glucagon-DTR
mice was done to assess the lasting impact of near-complete
a-cell ablation in adult animals. All DT-treated transgenic
mice were viable and healthy during the entire period of
analysis (up to 6 months after DT; i.e., 8-month-old mice),
which allowed us to evaluate their metabolic status.
Fasting and random-fed body weights were not affected
after a-cell ablation (Fig. 2A and Supplementary Fig 3A).
Surprisingly, DT-treated animals did not exhibit reduced
glycemia compared with controls during fasting or in
random-fed conditions (Fig. 2B and Supplementary Fig.
3B). In addition, glycemia was not signiﬁcantly changed,
even after a prolonged starvation (27-h fasting; Supple-
mentary Fig. 3C). Furthermore, DT-treated Glucagon-DTR
mice displayed normal insulin sensitivity and were able to
recover a normal glycemic level after an insulin-induced
hypoglycemia (Fig. 2C).
Because the counter-regulatory response was not im-
paired in a-cell–depleted mice, we veriﬁed their circulat-
ing glucagon levels. One week after DT, transgenic animals
were hypoglucagonemic (38.7 6 1.2, n = 10), with a 35%
reduction in fasting plasma glucagon compared with con-
trols (59.3 6 4.5 pg/mL, n = 14; P = 0.001; Fig. 2D). The
observed plasma glucagon levels were surprisingly high
considering the 98% a-cell loss; we thus explored whether
extrapancreatic glucagon was produced in this condition.
We found that glucagon was not ectopically secreted from
the intestine, because 1) no glucagon-expressing cells
were found in the duodenum, jejunum, or ileum (2,261 villi
from 4 mice were scored), and 2) no glucagon protein was
detected in intestinal extracts 1 week after a-cell removal
(Supplementary Fig. 2A and B). Instead, it is likely that the
very few pancreatic a-cells that escaped DT accounted for
the relatively high glucagonemia found in Glucagon-DTR
mice after extreme a-cell ablation (Fig. 2E and F; Supple-
mentary Table 2). We therefore measured glucagon secre-
tion from perfused pancreata after ablation. Interestingly,
basal pancreatic glucagon secretion in DT-treatedGlucagon-
DTR mice was similar to that of controls, thus conﬁrming
the pancreatic origin of circulating glucagon after a-cell loss
(Fig. 2G). The increase in glucagon secretion upon secre-
tagogue (arginine) induction was very moderate in ablated
mice, most likely reﬂecting the low amount of remnant
a-cells (Fig. 2G and H).
We subsequently assessed how the moderate hypo-
glucagonemia affects hepatic function. The mRNA levels
of hepatic gluconeogenic enzymes glucose-6-phosphatase
(G6Pase) and PEPCK were not signiﬁcantly changed 1
week after a-cell loss in Glucagon-DTR mice (Supple-
mentary Fig. 3D). In agreement with this, gluconeogenesis
was unaffected in these animals, as assessed by a pyruvate
tolerance test (PTT; Supplementary Fig. 3E and F). In-
terestingly, glucose mobilization after intraperitoneal glu-
cagon injection (glucagon tolerance test) was increased
after a-cell ablation (Supplementary Fig. 3G and H). This
increased glucagon sensitivity correlated with an observed
tendency toward a slight increase in the transcription of
hepatic GcgR and glycogen phosphorylase (GP) the key
enzyme involved in glycogenolysis (Supplementary Fig. 3D).
Taken together, these observations show that the control
of blood glucose is normal 1 week after a-cell ablation and
suggest that 2% of the a-cell mass is enough to maintain
a plasma glucagon level sufﬁcient to ensure normoglycemia
under basal conditions. Furthermore, the decrease in cir-
culating glucagon is rapidly compensated by enhanced
glucagon sensitivity and glucose mobilization from the liver.
b-Cell function is unaltered after extreme a-cell
ablation. a-Cells interact with b-cells, most likely by lo-
cal intraislet interactions, and a- and b-cells express in-
sulin and glucagon receptors, respectively (3,4,16–18). We
thus assessed whether a-cells are important for adequate
b-cell function. Pancreatic insulin content was unchanged
after DT, indicating that near-total a-cell ablation has no
effect on global insulin production (Fig. 3A). Glucagon-DTR
mice were also able to recover normoglycemia after glu-
cose challenge (glucose tolerance test), either 1 week or
6 months after DT (Fig. 3B and Supplementary Fig. 4) and
did not exhibit any defects in basal or glucose-stimulated
insulin secretion, as shown by pancreas perfusion experi-
ments (Fig. 3C). These results, together with the long-term
follow-up of glycemia in a-cell–depleted Glucagon-DTR
mice, reveal that massive loss of a-cells does not affect
blood glucose homeostasis or b-cell function.
Limited a-cell regeneration after extreme a-cell
ablation. One week after DT administration, the total
pancreatic glucagon content had dropped to 0.86% of
control level, but 1 and 6 months later, it was increased
by a factor of 6.7- and 14-fold, respectively (Fig. 4A and
Table 1). Basal glucagonemia was normal in Glucagon-
DTR mice (n = 4) 6 months after a-cell destruction (63.0 6
0.9 vs. 64.2 6 0.4 pg/mL in controls, n = 3; Fig. 2D). These
observations are consistent with 1) increased glucagon
production and secretion with time, by the few remaining
a-cells, and 2) the regeneration of new a-cells, or both.
To explore these possibilities, we assessed the number of
a-cells present in the pancreas 1 week, 1 month, and
6 months after DT (Supplementary Table 1). The total
F. THOREL AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 60, NOVEMBER 2011 2873
number of a-cells remained unchanged between 1 week
and 1 month after DT, but was doubled at 6 months, from
0.17 at 1 month to 0.35 cells/mm2 5 months later (P =
0.0286; Fig. 4B and Table 1). The number of islets was
similar between untreated and DT-treated animals at all
intervals, suggesting that new islets are not formed after
a-cell ablation (Fig. 4C and Table 1). The number of islet
sections containing at least 1 a-cell did not increase
during the regeneration period under study: the percentage
of sections containing a-cells dropped 1 week after DT
by about 10-fold compared with untreated controls
and remained stable thereafter (Fig. 4D and Table 1).
FIG. 1. a-Cell ablation in Glucagon-DTR mice. A: DT injection triggers a-cell ablation in Glucagon-DTR transgenic mice but not in wild-type mice.
Two days after DT injection, dying cells are detected by TUNEL, mainly at islet periphery in Glucagon-DTR animals (middle). At 1 week after DT
injection, islets in transgenic mice are devoid of glucagon-expressing cells (right). The dashed lines delineate islets. Scale bars = 20 mm. B: At 1
week after DT treatment, 97.9% of glucagon-expressing cells were destroyed (*P = 0.05, one-tailed Mann-WhitneyU test; values in Table 1). C: At 1
week after DT, pancreatic glucagon content was reduced to 0.86% of control (***P = 0.0001, one-tailed Mann-Whitney U test; values in Table 1).
(A high-quality digital representation of this ﬁgure is available in the online issue.)
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Nevertheless, among the islets that contained a-cells, the
number of a-cells per islet section was almost doubled 6
months after DT, from 1.58 at 1 month to 2.48 a-cells/
a-cell–containing islets (P = 0.0286; Fig. 4E and Table 1).
These ﬁndings suggest that the doubling in a-cells ob-
served 6 months post-DT was not due to the appearance
of new glucagon-expressing cells in islets devoid of
a-cells. Furthermore, we found that a-cell apoptosis and
proliferation were not increased at any time after DT
administration, thus suggesting that the low a-cell re-
generation observed after massive a-cell ablation was
not the consequence of a high rate a-cell turnover
(Supplementary Figs. 5 and 6).
The number of glucagon-positive cells located outside of
islets was decreased after DT treatment by about eightfold 1
week after DT, from 0.0604 to 0.007 a-cells/mm2 (P = 0.05),
indicating that DT also kills extrainsular glucagon–
expressing cells (Fig. 4F and Table 1). Interestingly, the
extrainsular a-cell number always remained lower than
that of controls at each interval.
Altogether, these results suggest that 1) although the
a-cell number remains unchanged during the ﬁrst month
after ablation, the very few spared a-cells increase their
glucagon content; 2) the doubling in the a-cell number seen
6 months after DT is mainly due to the increase of glucagon-
expressing cells in islets that retained at least one a-cell
after DT, and 3) there is no evidence of a-cell neogenesis
from unidentiﬁed pancreatic precursors in extraislet struc-
tures or in islets totally devoid of a-cells after DT.
We noted here that an in vivo cell lineage clonal
analysis showed precisely one a-cell doubling during the
ﬁrst 6 months of postnatal life in normal mice (19).
b-Cells do not reprogram to glucagon expression
upon a-cell loss. We recently showed that adult a-cells
spontaneously reprogram to acquire b-cell characteristics
after extreme, near-total b-cell destruction (13). We have
now investigated whether the reverse b-cell to a-cell
transdifferentiation also occurs spontaneously after a-cell
ablation; that is, if glucagon-expressing cells found several
months after DT administration were indeed b-cells that
had been reprogrammed to glucagon production after
a-cell loss. For this purpose, we performed a conditional cell
lineage tracing using RIP-CreERT, Rosa26YFP, Glucagon-
DTR transgenic mice (Fig. 5A). We irreversibly labeled
b-cells with the yellow ﬂuorescent protein (YFP) by the
administration of tamoxifen before a-cell ablation (Fig. 5B).
DT was given to ablate a-cells 2 weeks later. At 1 and 6
months after DT, none of the few glucagon-expressing cells
found were YFP-positive (634 islets from 6 mice were
scored and 256 glucagon-positive cells analyzed), whereas
almost all b-cells were ﬂuorescently tagged (Fig. 5C–J). In
conclusion, the glucagon-expressing cells present after
massive a-cell ablation are not reprogrammed b-cells.
Taken together, these observations suggest that the few
newly formed a-cells in Glucagon-DTR mice mainly arise
within islets retaining at least one a-cell after DT, likely
through a-cell replication (one event, on average, between 1
and 6 months). Several elements support this view: 1) the
number of a-cell–containing islets did not increase with
time after ablation, 2) the number of glucagon-positive cells
increased by a factor of two only in a-cell–containing islets,
and 3) the b-cell lineage-tracing revealed that b-cells do
not transdifferentiate spontaneously into a-cells.
Near-total a-cell loss does not prevent diabetes. In-
hibition of glucagon signaling (GcgR2/2 mice) was recently
shown to prevent STZ-induced diabetes (6). We thus as-
sessed whether near-total a-cell ablation in Glucagon-DTR
mice affects or prevents hyperglycemia. For this purpose,
Glucagon-DTR mice were treated 1 week after DT with
a high dose of STZ (200 mg/g) to induce ;90% b-cell re-
moval (Fig. 6A–G). Interestingly, mice that had only residual
a-cells (arrowheads in Fig. 6D and G) became overtly hy-
perglycemic and lost weight after b-cell destruction, like
diabetic mice with normal a-cell mass (Fig. 6H and I).
TABLE 1
Glucagon and a-cell content in the pancreas of Glucagon-DTR mice
Control mice DT-treated mice
P
% of
control
Fold
changeVariable Time post-DT Mean 6 SEM n Mean 6 SEM n
Pancreatic glucagon content
(pg/mg pancreas) 1 week 2,744 6 156.4 10 23.52 6 1.3 6 * 0.86 2116.7
1 month 2,905.233 6 276.9 6 157.9 6 16.4 4 † 5.44 218.4
6 months 3,320.475 6 292.2 4 331.4 6 42.7 5 † 9.98 210.0
a-Cell number/mm2 pancreas 1 week 7.02 6 1.80 3 0.15 6 0.03 3 ‡ 2.10 247.5
1 month 12.50 6 1.76 3 0.17 6 0.03 3 ‡ 1.40 271.6
6 months 9.87 6 1.07 4 0.35 6 0.04 4 ‡ 3.51 228.5
Total islet number/mm2 pancreas 1 week 0.96 6 0.08 3 1.15 6 0.14 3 NS — —
1 month 1.18 6 0.12 3 1.09 6 0.02 3 NS — —
6 months 1.42 6 0.17 4 1.36 6 0.17 4 NS — —
a-Cell–containing islet sections
(% of islet sections) 1 week 77.48 6 6.2 3 7.52 6 0.36 3 ‡ 9.71 210.3
1 month 81.31 6 4.0 3 10.18 6 1.78 3 ‡ 12.52 28.0
6 months 70.47 6 2.7 4 10.33 6 1.45 4 ‡ 14.66 26.8
a-Cell number/a-cell–containing
islet section 1 week 8.79 6 1.2 3 1.48 6 0.14 3 ‡ 16.88 25.9
1 month 13.18 6 1.4 3 1.58 6 0.03 3 ‡ 12.01 28.3
6 months 9.46 6 0.6 4 2.48 6 0.22 4 ‡ 26.22 23.8
Extrainsular a-cells/mm2 pancreas 1 week 0.0604 6 0.019 3 0.007 6 0.004 3 ‡ 12.10 28.3
1 month 0.0184 6 0.008 3 0.003 6 0.002 3 ‡ 17.29 25.8
6 months 0.0433 6 0.005 4 0.016 6 0.007 4 ‡ 36.04 22.8
*P # 0.005. †P # 0.01. ‡P # 0.05.
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FIG. 2. Extreme a-cell loss moderately decreases circulating glucagon and has no effect on the counter-regulatory response. Evolution of body
weight (A) and glycemia (B) in fasted controls (n = 3; DT-untreated, black ◆) and DT-treated (n = 3; red▲) Glucagon-DTR mice. C: Glycemia
after insulin-induced hypoglycemia 1 week after a-cell ablation. Blood glucose increased in both DT-treated mice (red▲) and controls (black◆)
after an insulin challenge (n = 3/group). D: Plasma glucagon 1 week and 6 months after DT (red □) injections and in control (black □) mice.
Glucagonemia was signiﬁcantly reduced by 35% 1 week after DT (***P = 0.001) but returned to normal levels 6 months later (values in Sup-
plementary Table 2). Confocal images of pancreatic sections stained for insulin (green) and glucagon (red) in controls (E) and Glucagon-DTR
mice (F). Very few pancreatic a-cells can be observed 1 week after DT. E’ and F’: higher magniﬁcation of the dotted areas depicted in E and F,
respectively. Scale bars = 100 mm in E and F and 20 mm in E’ and F’. G: Arginine-induced glucagon secretion from perfused pancreas 1 week after
DT or in controls. H: Quantiﬁcation of arginine-induced glucagon secretion upon arginine stimulation (1,290.2 6 281.9 for controls, and 423.3 6
85.3 pg/mL for DT-treated Glucagon-DTR mice; *P = 0.014). (A high-quality digital representation of this ﬁgure is available in the online issue.)
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Similarly, the simultaneous coablation of b- and a-cells (in
Glucagon-DTR, RIP-DTR double transgenic mice) (13) also
induced hyperglycemia and cachexia (Supplementary Fig. 7).
These results show that near-total a-cell ablation does not
prevent diabetes, contrary to what happens in GcgR2/2mice
(6). This was consistent with the unaltered glucagon secre-
tion and counter-regulatory response after removal of 98% of
a-cells under physiologic conditions.
DISCUSSION
We have shown that near-total a-cell loss in adult mice has
little effect on glucagonemia and no apparent effect on
b-cell function or glucose homeostasis. This reveals that 2
to 4% of the normal a-cell mass is astonishingly sufﬁcient
to produce enough glucagon to ensure glycemic control
under basal conditions. Massive a-cell loss is associated
with a rapid enhancement of glucagon sensitivity, which
allows increased glucose mobilization, even if the decrease
in glucagonemia is very mild.
A corollary of this observation is that the normal amount
of pancreatic a-cells apparently exceeds the physiologic
requirement for proper blood glucose homeostasis. Indeed,
the total glucagon found in the pancreas when only 2% of
the a-cells remain was sufﬁcient to maintain normogluca-
gonemia. A simple calculation reveals that if all pancreatic
glucagon found 1 week after a-cell loss (;7,400 pg; Supple-
mentary Table 2) were entirely released at once into the
circulation, glucagonemia would be more than 120-fold
higher than the normal value of about 60 pg (Supple-
mentary Table 2). The amount of glucagon measured in
plasma after 98% a-cell ablation (;40 pg; Supplementary
Table 2) only represents 0.5% of the residual pancreatic
glucagon content produced by the remaining 2% of a-cells
(7,400 pg). This suggests that the intracellular glucagon
store in the remaining a-cells is, in principle, sufﬁcient to
maintain basal glucagonemia. However, because plasma
glucagon has a half-life of only 2 min (20–22), sustained
glucagon biosynthesis after a-cell ablation is mandatory
to maintain glucagonemia and pancreatic content over
time. Indeed, in absence of glucagon biosynthesis, all pan-
creatic glucagon stocks found after DT should theoretically
be ﬁnished within ;6 h vs. ;17 days in control mice with
normal a-cell mass (estimated considering the observed
pancreatic glucagon contents and glucagon half-life).
In agreement with this, we found that although the number
of a-cells had not increased 1 month after the ablation, the
glucagon content per cell had doubled. In this situation,
the lack of response of the a-cell–ablated pancreata to ar-
ginine suggests that the few remaining a-cells have reached a
maximum secretion capacity or that glucagon biosynthesis is
rate limiting, or both. The inability of Glucagon-DTR mice to
ensure normoglucagonemia 1 week after DT, despite having
sufﬁcient pancreatic glucagon, indicates that glucagon se-
cretion is limited; however, because two-thirds of normal
plasma glucagon level is ensured by just 2% of normal a-cell
mass, this indicates that a-cells display a huge secretory
capacity. This property may contribute to the excessive
glucagon secretion observed in diabetic patients. Alter-
natively, our observations also suggest that in normal
conditions, with a normal a-cell mass, glucagon secretion
(relative to a-cell number) is very low.
It is therefore intriguing to observe that a-cells are so
numerous. They may somewhat be required for proper
endocrine pancreas development. Alternatively, or in ad-
dition, their numbers may reﬂect the effect of selection
pressure during evolution: most species must often thrive
through long periods of sustained starvation, and glucagon
facilitates glucose mobilization during food deprivation. In
the latter perspective, the massive loss of a-cells, which
we report here, was associated with a rapid enhancement
of glucagon sensitivity, which allows an increased glucose
mobilization likely through glycogenolysis, rather than glu-
coneogenesis, as revealed with glucose tolerance tests and
a tendency to express higher levels of liver GcgR and GP.
Interestingly, we have seen that extreme a-cell removal
in stressful situations, such as prolonged starvation and
insulin-induced hypoglycemia, has no obvious consequences
on fasting blood glucose and normoglycemia recovery.
Furthermore, Unger and colleagues (6) reported that in-
hibition of glucagon signaling prevented STZ-induced di-
abetes in mice. By contrast, we show here that near-total
a-cell ablation does not prevent hyperglycemia, indicating
that a minimal fraction of the a-cell mass is sufﬁcient to
mediate normal glucagon signaling. Together, these com-
bined observations strongly suggest that a total a-cell loss,
or glucagon-signaling blockade, would be required to
prevent hyperglycemia and diabetes after massive b-cell
destruction.
FIG. 3. b-Cell function is unaltered after a-cell ablation. A: Pancreatic insulin content measured 1 week after DT. Consistent with the speciﬁcity of
a-cell ablation, pancreatic insulin content was unaffected after DT (control: 131.1 6 5.8, n = 6; DT: 134.0 6 11.0 ng/mg of pancreas, n = 7).
B: Glucose tolerance test. DT-treated Glucagon-DTR mice (red▲) were not intolerant to glucose 1 week after massive a-cell ablation (n = 6 for
each group; control, black ◆). C: Insulin secretion measured from perfused pancreas after glucose stimulation. No signiﬁcant change in insulin
secretion was observed 1 week after a-cell ablation (n = 4 for each group).
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FIG. 4. Changes in pancreatic glucagon content and a-cell number after near-total a-cell loss. A: Pancreatic glucagon content was increased almost
sevenfold between 1 week and 1 month (from 23.52 to 157.9 pg/mg; **P = 0.0048, one-tailed Mann-Whitney U test) and doubled between 1 and 6
months (157.9 to 331.4 pg/mg; *P = 0.0317, one-tailed Mann-Whitney U test) in DT-treated animals. B: Pancreatic a-cell number was not increased
between 1 week and 1 month after DT but was doubled at 6 months. C: The total number of islets (deﬁned as clusters of at least three b-cells)
remained unchanged after a-cell ablation. D: The number of islet sections containing at least one a-cell was dramatically reduced after DT
treatment, throughout the whole period of analysis. E: The number of a-cells in islet sections containing a-cells after DT treatment was almost
doubled at 6 months. F: The number of a-cells located outside of islets was always lower in DT-treated mice than in controls and did not increase
signiﬁcantly with time after DT. A–F: Black ◆: control; red▲: DT-treated mice.
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FIG. 5. Newly formed a-cells after ablation are not reprogrammed b-cells. A: Transgenes required for the inducible b-cell tracing and a-cell
ablation. B: Experimental design for irreversible labeling of adult b-cells before a-cell ablation. C–F: Almost all b-cells were YFP-labeled after
tamoxifen (TAM) administration in control animals (DT-untreated). G–J: At 6 months after DT, none of the very rare glucagon-expressing cells
were YFP-positive (the arrowhead points to one a-cell, also shown in the top right inset at higher magniﬁcation). Scale bars = 20 mm. (A high-
quality digital representation of this ﬁgure is available in the online issue.)
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FIG. 6. a-Cell ablation does not prevent streptozotocin (STZ)-induced diabetes. A: Experimental design. One high dose of STZ (200 mg/g of mouse
weight) was administered to Glucagon-DTR mice to ablate b-cells 1 week after massive DT-mediated a-cell removal. Animals were killed 2 weeks
after STZ. B–G: Confocal images of pancreatic sections show DT-mediated a-cell ablation and STZ-mediated b-cell removal. White arrowheads
show remaining a-cells after DT. Scale bars = 20 mm. H: Follow up of glycemia. All STZ-treated mice become hyperglycemic irrespective of DT
administration. By contrast, animals that did not receive STZ remain normoglycemic (red◆: Glucagon-DTR mice treated with both DT and STZ,
n = 6; black ▼: Glucagon-DTR mice treated only with STZ, n = 6; black ■: untreated Glucagon-DTR mice, n = 3; red ▲: Glucagon-DTR mice
treated only with DT). I: Body weight 15 days after STZ. All mice treated with STZ lose weight and develop typical diabetes symptoms. (A high-
quality digital representation of this ﬁgure is available in the online issue.)
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Cell–cell signaling between a- and b-cells is thought to be
essential for proper blood glucose homeostasis (4), but the
direct, physical inﬂuence of a-cells on glucose-stimulated
insulin release has never been studied in vivo. We know
b-cell activity is independent of glucagon signaling because
it remains unaltered upon treatment with GcgR antagonists
or in GcgR2/2 mice (8,23), that is, in situations where
a-cells are abundant or expanded. In DT-treated Glucagon-
DTR mice, however, almost all islets are totally devoid of
a-cells, which prevents any paracrine intraislet direct in-
teraction between these two cell types. Yet, glucose homeo-
stasis in this situation is not affected under basal conditions,
thus suggesting that local a-cell–b-cell interactions are dis-
pensable for adequate b-cell function. This conclusion
could not be reached in previous studies because the ani-
mal model reported here is the ﬁrst in which adult mice
have nearly normal glucagonemia, yet lack most a-cells.
a-Cell hyperplasia has been reported in patients bearing
mutations in the GcgR gene (24,25) and in mice exhibiting
glucagon deﬁciency, such as in glucagon2/2, GcgR2/2,
and PC2 2/2 mice, as well as in wild-type mice treated
with GcgR-neutralizing antibody (7,8,26–29). In all these
situations, the formation of new a-cells likely represents
a compensatory response to deﬁcient glucagon signaling.
The origin of newly formed a-cells in glucagon-deﬁcient
conditions is not known. The continuous emergence of
a-cells from pancreatic ductal Neurog-3–expressing cells
was reported in mice expressing the b-cell–speciﬁc tran-
scription factor paired box gene 4 (PAX4) in embryonic
a-cells (30). In these animals, a-cells reprogram toward the
b-cell phenotype upon PAX4 misexpression, leading to
a substantial reduction in postnatal a-cell numbers. The
authors proposed that glucagon deﬁciency was the driving
force for the continuous appearance of a-cells, yet gluca-
gonemia was not measured in their study, and the a-cell
deﬁcit was similar to the one observed here in DT-treated
Glucagon-DTR mice. By contrast, there is no evidence for
ductal a-cell neogenesis in Glucagon-DTR mice: the rare
a-cells found after DT were never preferentially located
within or near ducts. This difference may be attributed to
the perturbed metabolic status of mice over-expressing
PAX4, which exhibit strong b-cell hyperplasia and very
high insulinemia, likely resulting in an abnormally elevated
insulin-to-glucagon balance.
We recently reported that adult a-cells reprogram to
insulin production after extreme b-cell ablation (13). Here,
we explored whether b-cells can reprogram to produce
glucagon after massive a-cell loss and failed to observe
any such b- to a-cell conversion. However, the interconver-
sion between a- and b-cells may occur in both directions
when conditions are appropriate. Indeed, it has been shown
that 1) the ectopic expression of the a-cell–speciﬁc tran-
scription factor ARX or 2) the conditional inactivation of
the DNA methyltransferase gene Dnmt1 in embryonic
b-cells converts them to the a-cell phenotype (31,32).
After b-cell destruction in RIP-DTR mice, ;5% of adult
a-cells spontaneously undergo cell reprogramming; this
limited number of cells probably determines the extent of
b-cell recovery in RIP-DTR transgenic mice (13). This ob-
servation alone makes us speculate that promoting the
conversion of most a-cells to b-cells, if it could be achieved,
might represent an attractive therapeutic strategy for di-
abetes, once we learn how to modulate autoimmunity. In
this regard, it was unclear what the minimal a-cell mass
is to ensure enough glucagon production should a-cell
reprogramming become a therapy to treat diabetes. The
present work reveals that 2 to 4% of functional a-cells is
sufﬁcient to guarantee the glycemic control, at least under
basal conditions. Reduction of the a-cell pool by reprog-
ramming to b-cells could have the additional beneﬁcial ef-
fect of preventing the glucagon excess typical of type 1
diabetes, which enhances the risk for hyperglycemia and
ketoacidosis in patients afﬂicted with the disease (5).
RESEARCH DESIGN AND METHODS
Mice. The Glucagon-DTR transgenic mice were generated by pronuclear in-
jection, as described (13). Brieﬂy, heparin-binding epidermal growth factor-
like growth factor (i.e., the natural receptor to DT, DTR) cDNA was subcloned
downstream of a 1.6-kb-long rat glucagon promoter fragment (14). The RIP-
DTR, RIP-CreERT, and R26-YFP mice were previously described (33,34).
Animals were housed and cared for according to the guidelines of the Direction
Générale de la Santé of the Canton de Genève.
Glucose, pyruvate, insulin tolerance tests. Glucose (1.1 g/kg of body wt;
84100, Sigma, St. Louis, MO), pyruvate (2 g/kg; P2256, Sigma) and glucagon
(1 mg/kg; H-6790, Bachem, Bubendorf, Switzerland) were injected intra-
peritoneally after overnight fasting, when indicated. Insulin (0.5 units/kg;
Actrapid, Novo Nordisk A/S, Bagsværd, Denmark) was injected after a 6-h fast.
Pancreas perfusion. Mice were anesthetized with sodium pentothal (100
mg/kg i.p.) and prepared for pancreas perfusion, as described (35,36). Pancreata
were perfused with modiﬁed Krebs-Ringer HEPES buffer containing 4% dex-
tran (Pharmacosmos, Holbaek, Denmark) and 0.25% BSA at 37°C; the perfu-
sion rate was 1.5 mL/min. For equilibration, the pancreas was perfused for
30 min before collecting the efﬂux. Glucose and arginine were added to the
perfusion buffer as indicated in Figs. 2G–H and 3C. Insulin was measured
using an enzyme immunoassay kit (SPI-BIO, Massy, France). Glucagon was
determined by radioimmunoassay using an antiglucagon antibody (Dako
Diagnostics, Zug, Switzerland), as described previously (35).
Hormonemeasurements, immunoﬂuorescence, andmorphometric analyses.
Pancreatic glucagon and insulin (immunoassays) and morphometric analyses
were performed as described (13,37,38). Parafﬁn and cryostat sections were
5 mm or 10 mm thick, respectively. The antibodies used were: guinea pig anti-
porcine insulin (1:400, Dako), mouse anti-porcine glucagon (1:1,000, Sigma),
mouse anti-somatostatin (1:200, Beta Cell Biology Consortium, Nashville, TN),
rabbit anti-pancreatic polypeptide (1:200, Bachem), goat anti–glucagon-like
peptide 1 (1:200, Santa Cruz Biotechnology, Santa Cruz, CA), rabbit anti-
green ﬂuorescent protein (1:200, Molecular Probes Inc., Eugene, OR), and
anti-phosphohistone H3 (1:400, Millipore Corp., Billerica, MA). Secondary
antibodies were coupled to Alexa Fluor dyes 488, 568, or 647 (Molecular
Probes, Inc.), to Cy3, or to Cy5 (Jackson ImmunoResearch Laboratories, Inc.,
West Grove, PA). Transferase-mediated dUTP nick-end labeling (TUNEL) assay
was performed according to manufacturer’s instructions (Apoptag, Chemicon,
Temecula, CA).
Sections were examined with a Leica TCS SPE confocal microscope (Leica
Microsystems, Bannockburn, IL).
DT, STZ, and tamoxifen treatments. DT (D0564, Sigma) was given to
2-month-old mice in three intraperitoneal injections during 5 days, the second
and third doses on days 3 and 5, respectively. Each injection (200 mL) contained
504 ng of DT in 0.9% NaCl.
STZ (S0130; Sigma) was administrated in one injection (200 mg/g i.p.) after
a 4-h fast.
RIP-CreERT mice were given a freshly prepared tamoxifen suspension
with a gastric catheter, as previously described (13).
Quantitative PCR. Liver samples were frozen in liquid nitrogen and kept at2
80°C until use. Fragments of 30 mg were subsequently used for total RNA
isolation using the Qiagen RNeasy Mini kit (Qiagen, Valencia, CA) with small
modiﬁcations: due to high glycogen content in hepatocytes, we used 50%
ethanol instead of 70% ethanol, as recommended. Four samples per group
were analyzed in triplicates, and in a minimum of three independent runs. The
quantitative PCR was performed as previously described by us (13), using the
following primers:G6Pase forward (59-GTGGCTGGAGTCTTGTCAGG-39)/re-
verse (59-ATTGTAGATGCCCCGGATG-39),PEPCK forward (59-GATGACAT-
TGCCTGGATGAA-39)/reverse (59-CGTTTTCTGCTGGGTTGATAGCC-39),GcgR
forward (59-ACCAATGCCACCACAACC-39)/reverse (59-GGAGTACTTGTC-
GAAGGTTCTGTTAC-39), andGP forward (59-ATCAACCCATCCTCCATGTT-
39)/reverse (59-ACATGCAGGCAGTTCAGAAG-39).
Blood samples. Blood samples were collected from the tail vein of mice fasted
overnight.
Statistical analyses. One- or two-tailed Mann-Whitney U tests were used
when indicated, using GraphPad Prism 4.00 software (GraphPad, San Diego,
CA). Error bars in the ﬁgures represent the SEM.
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